title: Effect of sibutramine on weight reduction in women with polycystic ovary syndrome: a randomized, double-blind, placebo-controlled trial.
abstract: OBJECTIVE
  To examine the efficacy of sibutramine together with brief lifestyle modification for weight reduction in obese women with polycystic ovary syndrome (PCOS).
  
  
  METHODS
  Investigator-initiated, multicenter, double-blind, randomized, parallel-group clinical trial.
  
  
  METHODS
  Departments of Obstetrics and Gynecology in primary care, referral centers, and private practice.
  
  
  METHODS
  Forty-two patients with confirmed PCOS were included in the study, and 34 patients completed the study.
  
  
  METHODS
  Sibutramine 15 mg once daily together with brief lifestyle modification was compare with placebo together with brief lifestyle modification.
  
  
  METHODS
  The primary endpoint was to assess weight loss. Secondary endpoints included the efficacy of sibutramine for treatment of menstrual pattern and cardiovascular risk factors.
  
  
  RESULTS
  After 6 months the sibutramine group had lost 7.8 +/- 5.1 kg compared with a weight loss of 2.8 +/- 6.2 kg in the placebo group. Sibutramine treatment resulted in significant decreases in apolipoprotein B, apolipoprotein B/apolipoprotein A ratio, triglycerides, and cystatin C levels.
  
  
  CONCLUSIONS
  Sibutramine in combination with lifestyle intervention results in significant weight reduction in obese patients with PCOS. In addition to the weight loss, sibutramine seems to have beneficial effects on metabolic and cardiovascular risk factors.
authors.affiliation: Department of Obstetrics and Gynecology, Sunderby Hospital, Luleå, Sweden. Electronic address: asa.lindholm@nll.se.
authors.forename: Åsa
authors.initials: Å
authors.lastname: Lindholm
authors.affiliation: Department of Clinical Science, Obstetrics and Gynecology, University Hospital, Umeå, Sweden.
authors.forename: Marie
authors.initials: M
authors.lastname: Bixo
authors.affiliation: Department of Clinical Science, Obstetrics and Gynecology, University Hospital, Umeå, Sweden; Läkarhuset Björnen, Piteå, Sweden.
authors.forename: Inger
authors.initials: I
authors.lastname: Björn
authors.affiliation: Department of Obstetrics and Gynecology, Lund University Hospital, Lund, Sweden.
authors.forename: Pål
authors.initials: P
authors.lastname: Wölner-Hanssen
authors.affiliation: Department of Internal Medicine, Sunderby Hospital, Luleå, Sweden.
authors.forename: Mats
authors.initials: M
authors.lastname: Eliasson
authors.affiliation: Department of Clinical Chemistry, University Hospital, Uppsala, Sweden.
authors.forename: Anders
authors.initials: A
authors.lastname: Larsson
authors.affiliation: Department of Internal Medicine, University Hospital, Umeå, Sweden.
authors.forename: Owe
authors.initials: O
authors.lastname: Johnson
authors.affiliation: Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden.
authors.forename: Inger Sundström
authors.initials: IS
authors.lastname: Poromaa
mesh_terms: D000293:Adolescent; D000328:Adult; D001067:Appetite Depressants / Q000494:pharmacology / Q000627:therapeutic use*; D001835:Body Weight / Q000187:drug effects; D002318:Cardiovascular Diseases / Q000209:etiology; D003503:Cyclobutanes / Q000494:pharmacology / Q000627:therapeutic use*; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D008019:Life Style; D008599:Menstruation Disturbances / Q000097:blood / Q000188:drug therapy; D009765:Obesity / Q000097:blood / Q000188:drug therapy*; D011085:Polycystic Ovary Syndrome / Q000097:blood / Q000188:drug therapy*; D011446:Prospective Studies; D012307:Risk Factors; D012738:Sex Hormone-Binding Globulin / Q000378:metabolism; D015431:Weight Loss / Q000187:drug effects
chemical_list: D001067:Appetite Depressants; D003503:Cyclobutanes; D012738:Sex Hormone-Binding Globulin; C058254:sibutramine